Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.

Key facts

Study ID

NCT01527916

Run by

AbbVie (prior sponsor, Abbott)

People needed

438

Starts

2012-02-01

Expected to finish

2013-11-01

Last updated by the study team

2014-11-19

Who can join

Age: 55 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject and caregiver must voluntarily sign and date an informed consent. If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject.
• The subject is a male or female between the ages of 55 and 90 years, inclusive, at Screening Visit 1.
• The subject meets the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's disease.
• The subject has a Mini-Mental Status Examination (MMSE) total score of 10 to 24, inclusive, at Screening Visit 1.
• The subject has a Cornell Scale for Depression in Dementia (CSDD) score ≤ 10 at Screening Visit 1.
• The subject has a Modified Hachinski Ischemic Scale (MHIS) score of ≤ 4 at Screening Visit 1.
• With the exception of a diagnosis of mild to moderate AD and the presence of stable medical conditions, the subject is in general good health, based upon the results of medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).
• The subject has an identified, reliable caregiver who will provide support and ensure compliance with the study medication and procedures, and provide accurate information about the subject's status during the study.

You may not qualify if…

• The subject is currently taking or has taken a medication for the treatment of Alzheimer's disease or dementia within 60 days prior to Screening Visit 1, or is participating in cognitive therapy for the treatment of Alzheimer's disease or dementia.
• The subject has clinically significant abnormal laboratory values at Screening Visit 1 as determined by the investigator.
• The subject has a history of any significant neurologic disease other than Alzheimer's disease including Parkinson's disease, multi-infarct or vascular dementia, Huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy, multiple sclerosis, any seizures, mental retardation or a history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.
• In the opinion of the investigator, the subject has any clinically significant uncontrolled medical or psychiatric illness.
• The subject has a known hypersensitivity or intolerance to donepezil that lead to discontinuation or a known reported history of donepezil treatment failure.

Where it is running

• Site Reference ID/Investigator# 56503 — Delray Beach, Florida, United States
• Site Reference ID/Investigator# 56518 — Tampa, Florida, United States
• Site Reference ID/Investigator# 56514 — West Palm Beach, Florida, United States
• Site Reference ID/Investigator# 62611 — Elk Grove Village, Illinois, United States
• Site Reference ID/Investigator# 56506 — Staten Island, New York, United States
• Site Reference ID/Investigator# 82994 — Jenkintown, Pennsylvania, United States
• Site Reference ID/Investigator# 77636 — Wichita Falls, Texas, United States
• Site Reference ID/Investigator# 56504 — Bennington, Vermont, United States
• Site Reference ID/Investigator# 62565 — Gdynia, Poland
• Site Reference ID/Investigator# 62563 — Poznan, Poland
• Site Reference ID/Investigator# 62562 — Szczecin, Poland
• Site Reference ID/Investigator# 60945 — Kazan', Russia
• Site Reference ID/Investigator# 60955 — Kazan', Russia
• Site Reference ID/Investigator# 60954 — Kirov, Russia
• Site Reference ID/Investigator# 60951 — Moscow, Russia
• Site Reference ID/Investigator# 60959 — Moscow, Russia
• Site Reference ID/Investigator# 60946 — Novosibirsk, Russia
• Site Reference ID/Investigator# 60947 — Saint Petersburg, Russia
• Site Reference ID/Investigator# 60958 — Saint Petersburg, Russia
• Site Reference ID/Investigator# 60949 — Saint Petersburg, Russia
• Site Reference ID/Investigator# 60952 — Saint Petersburg, Russia
• Site Reference ID/Investigator# 60950 — Saratov, Russia
• Site Reference ID/Investigator# 60911 — Belville, South Africa
• Site Reference ID/Investigator# 76073 — Cape Town, South Africa
• Site Reference ID/Investigator# 60912 — George, South Africa

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.